DUBLIN, June 14, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it is hosting an investor conference call and audio webcast on Monday, June 20, 2016 at 4:30 p.m. EDT/9:30 p.m. IST to provide investors with an update on JZP-110, including a discussion of data presented at the 30th Annual Associated Professional Sleep Societies (APSS) Annual SLEEP meeting held June 11-15 in Denver, Colorado.
Interested parties may access the live audio webcast and download the accompanying slide presentation from the Investors section of the company's website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
Conference Call Details:
U.S. Dial-In Number: +1 503 343 6056
Outside the U.S. Dial-In Number: +1 855 353 7924
A replay of the conference call will be available through June 27, 2016 and accessible through dialing one of the following telephone numbers and entering the passcode:
Replay U.S. Dial-In Number: +1 404 537 3406
Replay Outside the U.S. Dial-In Number: +1 855 859 2056
An archive of the audio webcast will be available for at least one week on the Investors section of the company's website at www.jazzpharmaceuticals.com.
JZP-110 is a late-stage investigational wake-promoting agent being developed as a treatment for excessive sleepiness (ES) in adult patients with narcolepsy or with obstructive sleep apnea (OSA). Jazz Pharmaceuticals has worldwide development, manufacturing, and commercialization rights to JZP-110, excluding certain jurisdictions in Asia. The enrollment in the Phase 3 safety and efficacy studies of JZP-110 in the treatment of ES in narcolepsy and OSA patients is ongoing.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi) and Defitelio® (defibrotide sodium) in the U.S. and markets Erwinase® and Defitelio® (defibrotide) in countries outside the U.S. For more information, please visit www.jazzpharmaceuticals.com.
SOURCE Jazz Pharmaceuticals plc